KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. PMID 41297955 · J Eur Acad Dermatol Venereol · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis. PMID 41272415 · Int J Dermatol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial. PMID 41272211 · Diabetologia · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: A Randomized Pilot Study. PMID 41223739 · Arch Med Res · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. PMID 41193271 · Eur Urol Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). PMID 41073155 · Int J Gynecol Cancer · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy. PMID 41034645 · Pediatr Res · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study. PMID 40999072 · Prostate Cancer Prostatic Dis · 2026-Jun The study is a randomized trial of a surgical/procedural intervention (lymph node dissection) for prostate cancer and lacks a drug-containing intervention, which is a required criterion for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Breast Cancer Patients With Brain Metastases-A Phase 3 Open Label Randomized Study. PMID 40983872 · Asia Pac J Clin Oncol · 2026-Jun The record reports a Phase III randomized trial in human oncology with time-to-event efficacy endpoints (OS, PFS). However, the intervention compares two non-drug radiotherapy modalities (whole-brain radiotherapy vs. stereotactic radiosurgery) and does not include a drug-containing arm. Therefore, it does not meet the drug intervention criterion for this cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents. PMID 40763320 · JCO Oncol Pract · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial. PMID 40633684 · J Card Fail · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial. PMID 40619095 · J Am Acad Child Adolesc Psychiatry · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A multi-site feasibility study of a stepped-care telehealth intervention for depression and anxiety in post-treatment cancer survivors at community cancer clinics (WF-30917CD). PMID 39810026 · J Cancer Surviv · 2026-Jun The study is a randomized controlled trial in human cancer survivors, but it is a feasibility study (not Phase III/IIIb or Phase II/III), evaluates a non-drug psycho-oncology intervention (telehealth CBT), and uses patient-reported outcome measures (depression, anxiety, QOL) rather than time-to-event efficacy endpoints (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. PMID 42515859 · BJU Int · 2026-Jul-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Identifying subsets of patients with retroperitoneal sarcoma who benefit from radiotherapy: an Interpretable AI reanalysis of the STRASS randomised trial. PMID 42509079 · Lancet Digit Health · 2026-Jul-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Circulating Tumour DNA and Molecular Residual Disease in Oesophageal Cancer: Clinical Readiness, Evidence Gaps and Trial-Ready Applications. PMID 42508592 · Crit Rev Oncol Hematol · 2026-Jul-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). PMID 42507969 · J Clin Oncol · 2026-Jul-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. PMID 42507968 · J Clin Oncol · 2026-Jul-27 The record describes a published, original, primary analysis of a phase III randomized trial in human oncology with a drug intervention and time-to-event efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. PMID 42269244 · Eur J Cancer · 2026-Jul-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. PMID 42241967 · Eur J Cancer · 2026-Jul-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. PMID 42235464 · Eur J Cancer · 2026-Jul-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial. PMID 42501860 · Contemp Clin Trials · 2026-Jul-25 The record describes a Phase-unspecified randomized trial protocol (no results) with a drug intervention (adjuvant endocrine therapy) and a primary quality-of-life endpoint. It does not report original formal results for a time-to-event efficacy endpoint as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial. PMID 42501213 · J Gastrointest Cancer · 2026-Jul-25 The record describes a randomized trial in oncology with a drug intervention and a time-to-event secondary endpoint (OS), but the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, the primary efficacy endpoint is pathological complete response (pCR), which is not a time-to-event endpoint. While OS is a time-to-event endpoint, it is reported as an exploratory secondary outcome with immature results. Therefore, the trial does not meet the eligibility criteria for a definitive randomized trial with a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials. PMID 42499270 · Pediatr Blood Cancer · 2026-Jul-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. PMID 42498834 · Leukemia · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Blood-based cell-free DNA for addressing colorectal cancer screening disparities: a study protocol for a randomised trial. PMID 42498482 · BMJ Open · 2026-Jul-24 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PMID 42497381 · J Clin Oncol · 2026-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. PMID 42496861 · Adv Ther · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. PMID 42496653 · Oncologist · 2026-Jul-24 This is a Phase III, randomized, drug-intervention trial in advanced breast cancer, but it reports on visual safety and patient-reported outcomes, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the inclusion criteria for a time-to-event efficacy report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. PMID 42483956 · Expert Rev Anticancer Ther · 2026-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Acute skin toxicity and cosmesis outcome in non-metastatic breast cancer patients treated with ultrahypofractionated radiotherapy: a randomized controlled phase II clinical trial comparing proton versus photon radiotherapy. PMID 42183732 · J Radiat Res · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial. PMID 42493688 · Pituitary · 2026-Jul-23 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol 2026;89:437-45. PMID 42493340 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848. PMID 42493339 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. PMID 42493213 · J Immunother Cancer · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. PMID 42492498 · JMIR Res Protoc · 2026-Jul-23 This is a protocol for a proof-of-concept feasibility trial investigating a behavioral weight-loss intervention (intermittent fasting and exercise) among breast cancer survivors. It is not a randomized Phase III trial, does not involve a drug intervention, and does not report time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. PMID 42492022 · J Clin Oncol · 2026-Jul-23 Trial compares two radiotherapy fractionation schedules (drug-free intervention), not a drug-containing regimen. Meets all other criteria (Phase III, randomized, human oncology, time-to-event efficacy endpoints with original results) but fails the drug intervention requirement.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial. PMID 42492015 · J Clin Oncol · 2026-Jul-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. PMID 42489705 · Clin Cancer Res · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. PMID 42485627 · N Engl J Med · 2026-Jul-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review. PMID 42512424 · Cancers (Basel) · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study. PMID 42486309 · Int J Radiat Oncol Biol Phys · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. PMID 42486133 · Lancet · 2026-Jul-22 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. PMID 42485700 · ESMO Open · 2026-Jul-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation. PMID 42485590 · JCO Oncol Pract · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). PMID 42485106 · Clin Cancer Res · 2026-Jul-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Extent of Lymphadenectomy in Esophageal Cancer Surgery: Unresolved Issues in Prophylactic 3-Field Dissection. PMID 42482330 · J Chest Surg · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. PMID 42483812 · Biomol Biomed · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer. PMID 42481259 · Farm Hosp · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study. PMID 42480197 · ESMO Open · 2026-Jul-21 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and primary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and survival rates, meeting all eligibility criteria.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 7 Panel · risk visible